Shots:
- China’s NMPA has accepted the NDA for Nucala as an add-on treatment for COPD with eosinophilic phenotype based on P-III (MATINEE) study; global regulatory filings is ongoing
- The MATINEE study assessing Nucala (100mg, Q4W, SC) vs PBO in addition to inhaled triple therapy in COPD pts (n=804) with type 2 inflammation achieved its 1EP, showing significantly reduced mod. /sev. exacerbations over 52-104wks. Data to be highlighted at future conferences
- Nucala (mepolizumab) is a mAb that inhibits IL-5 to reduce blood eosinophil level for producing anti-inflammatory activity in eosinophilic asthma, EGPA & CRSwNP
Ref: GSK | Image: GSK
Related News:- GSK Reports the US FDA Approval of Penmenvy (MenABCWY Vaccine) for Protection Against Invasive Meningococcal Disease (IMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
